Replies to post #33958 on Ariad Pharmaceuticals Inc fka ARIA

[glass_half_full]

Most TKI's cross the BBB in fractions of plasma concentrations, Pona crosses in multiples

You know, now that you mention this, I think you've pointed that out before -- perhaps in the same terms!

Thanks -- interesting that pona seems to go in, stay in, and not cause problems.

[oldchemist4]

Thanks! A massive composition-of-matter & synthesis application with priority date in April/May 2011. Says a great deal about the quality of the ARIAD team.

Doesn't specifically mention glioblastoma (I may have missed it) but the opening sentence in the summary (which is what is read first in a patent search) is telling:

"It has been unexpectedly discovered that certain targeted TKI's cross the blood brain barrier....."

I know I am getting really boring with this, but these "off target" properties are going to be the real drivers of valuation.